Klinik & Poliklinik für Nuklearmedizin
TUM Klinikum Rechts der Isar
Publications

Peer-reviewed

  • Russelli L, De Rose F, Leone L, Reder S, Schwaiger M, D’Alessandria C*, Tei L*. A semi rigid novel hydroxamate AMPED-based ligand for 89Zr PET imaging.Molecules 2021; doi: 10.3390/molecules26195819.

     
  • Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, Rauscher I, Wurzer A, Wester HJ, Weber WA, D'Alessandria C*, Eiber M*. Pre-therapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC). J Nucl Med. 2021 Sep 16:jnumed.121.262671.

     
  • Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 Aug;22(8):1115-1125.

     
  • Yusufi N, Wurzer A, Herz M, D'Alessandria C, Feuerecker B, Weber W, Wester HJ, Nekolla S, Eiber M. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. J Nucl Med. 2021 Aug 1;62(8):1106-1111.

     
  • Birindelli G, Drobnjakovic M, Morath V, Steiger K, D'Alessandria C, Gourni E, Afshar-Oromieh A, Weber W, Rominger A, Eiber M, Shi K. Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?-An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. Cancers (Basel). 2021 Jul 8;13(14):3429.

     
  • Chantadisai M, Buschner G, Krönke M, Rauscher I, Langbein T, Nekolla SG, Schiller K, Heck MM, Maurer T, Wurzer A, Wester HJ, D'Alessandria C, Weber W, Eiber M. Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard. J Nucl Med. 2021 Jul 1;62(7):968-974.

     
  • Peplau E, De Rose F, Eichinger A, Reder S, Mittelhäuser M, Scafetta G, Schwaiger M, Weber WA, Bartolazzi A, D'Alessandria C, Skerra A. Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo. Sci Rep. 2021 Apr 1;11(1):7358.

     
  • Rauscher I, Karimzadeh A, Schiller K, Horn T, D'Alessandria C, Franz C, Wörther H, Nguyen N, Combs SE, Weber WA, Eiber M. Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med. 2021 Mar 12:jnumed.120.260091. doi: 10.2967/jnumed.120.260091. Online ahead of print.

     
  • Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C*, Morgenstern A*, Eiber M*. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2021 Mar;79(3):343-350.

     
  • Varasteh Z, De Rose F, Mohanta S, Li Y, Zhang X, Miritsch B, Scafetta G, Yin C, Sager HB, Glasl S, Gorpas D, Habenicht AJR, Ntziachristos V, Weber WA, Bartolazzi A, Schwaiger M, D'Alessandria C. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb. Theranostics. 2021 Jan 1;11(4):1864-1876.

     
  • Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C, D'Alessandria C, Retz M, Weber WA, Eiber M. Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020 Oct;61(10):1476-1483.

     
  • Peplau E, De Rose F, Reder S, Mittelhäuser M, Scafetta G, Schwaiger M, Weber WA, Bartolazzi A, Skerra A, D'Alessandria C. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer. Thyroid. 2020 Sep;30(9):1314-1326.

 

  • Russelli L, Martinelli J, De Rose F, Reder S, Herz M, Schwaiger M, Weber W, Tei L, D'Alessandria C. Room Temperature Al18 F Labeling of 2-Aminomethylpiperidine-Based Chelators for PET Imaging. ChemMedChem. 2020 Feb 5;15(3):284-292.

     
  • Gafita A, Wang H, Tauber R, D'Alessandria C, Weber WA, Eiber M. Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213.

     
  • Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, de Oliviera Bianchi H, Audehm S, Wagner R, Bräunlein, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D`Alessandria C, Krackhardt AM. T-cell functionality testing is highly relevant to develop novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as attractive target. Theranostics. 2018 Nov 28;8(21):6070-6087. doi: 10.7150/thno.27275.

     
  • Karimi Ghodoosi E, D'Alessandria C, Li Y, Bartel A, Köhner M, Höllriegl V, Navab N, Eiber M, Li WB, Frey E, Ziegler S. The effect of attenuation map, scatter energy window width, and volume of interest on the calibration factor calculation in quantitative 177Lu SPECT imaging: Simulation and phantom study. Phys Med. 2018 Dec;56:74-80. doi: 10.1016/j.ejmp.2018.11.009.

     
  • Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30873-X. doi: 10.1016/j.eururo.2018.11.016.

     
  • Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, D'Alessandria C, Weber WA, Eiber M, Tauber R. Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC. J Nucl Med. 2018 Nov 15. pii: jnumed.118.215715. doi: 10.2967/jnumed.118.215715.

     
  • De Rose F, Braeuer M, Braesch-Andersen S, Otto AM, Steiger K, Reder S, Mall S, Nekolla S, Schwaiger M, Weber WA, Bartolazzi A, D'Alessandria C. Galectin-3 targeting in thyroid orthotopic tumors opens new ways to characterize thyroid cancer. J Nucl Med. 2018 Oct 25. pii: jnumed.118.219105. doi: 10.2967/jnumed.118.219105.

     
  • Stangl S, Tei L, De-Rose F, Reder S, Martinelli J, Sievert W, Shevtsov M, Öllinger R, Rad R, Schwaiger M, D’Alessandria C*, Multhoff G*. Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[89Zr] for tumor-specific PET/CT imaging. Cancer Res. 2018 Nov 1;78(21): 6268-6281.

     
  • Kletting P, Thieme A, Eberhardt N, Rinscheid A, D'Alessandria C, Allmann J, Wester HJ, Tauber R, Beer AJ, Glatting G, Eiber M. Modeling and predicting tumor response in radioligand therapy. J Nucl Med. 2019 Jan; 60 (1): 65-70. doi: 10.2967/jnumed.118.210377. Epub 2018 May 10.

     
  • Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B, D'Alessandria C, Pfob C, Nekolla S, Apostolidis C, Mirzadeh S, Gschwend JE, Schwaiger M, Scheidhauer K, Morgenstern A. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur J Nucl Med Mol Imaging. 2018 Apr 11. doi: 10.1007/s00259-018-4003-6. [Epub ahead of print]

     
  • Begum NJ, Thieme A, Eberhardt N, Tauber R, D’Alessandria C, Beer AJ, Glatting G, Eiber M, Kletting P. The effect of total tumor volume on the biologically effective dose of tumor and kidneys for 177Lu-labelled PSMA peptides. J Nucl Med. 2018 Jun;59(6):929-933.

     
  • Pfob CH, Eiber M, Luppa P, Maurer F, Maurer T, Tauber R, D'Alessandria C, Feuerecker B, Scheidhauer K, Ott A, Heemann U, Schwaiger M, Schmaderer C. Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. EJNMMI Res. 2018 Feb 27;8(1):17. doi: 10.1186/s13550-018-0370-z.
  • Yusufi N, Mall S, Bianchi HO, Steiger K, Reder S, Klar R, Audehm S, Mustafa M, Nekolla S, Peschel C, Schwaiger M, Krackhardt AM, D'Alessandria C. In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET. Theranostics. 2017 Jun 15; 7(9): 2402-2416.
  • D’Alessandria C, Braesch-Andersen S, Bejo K, Reder S, Blechert B, Schwaiger M,  Bartolazzi A. Noninvasive in vivo imaging and biological characterization of thyroid tumors by immunoPET targeting of Galectin-3. Cancer Res. 2016 Jun 15; 76(12): 3583-92.
  • Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendlder WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017 Mar;58(3):445-450.
  • Mendler CT, Feuchtinger A, Heid I, Aichler M, D'Alessandria C, Pirsig S, Blechert B, Wester H-J, Braren R, Walch A, Skerra A, Schwaiger M. Tumor uptake of anti-CD20 Fabs depends on tumor perfusion. J Nucl Med. 2016 Dec; 57(12): 1971-1977.
  • Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2016 Aug; 196(2):382-91.
  • Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D’Alessandria C, Krackhardt AM. Immuno-PET imaging of engineered human T cells in tumors. Cancer Res. 2016 Jul 15; 76(14):4113-23.
  • D'Alessandria C, Pohle K, Rechenmacher F, Neubauer S, Notni J, Wester HJ, Schwaiger M, Kessler H, Beer AJ. In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366. Eur J Nucl Med Mol Imaging. 2016; 43 (5): 953-63.
  • Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D'Alessandria C, Wester HJ, Reuning U, Corti A, Schwaiger M, Kessler H. Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. Angew Chem Int Ed Engl. 2013; 52 (44): 11656-9.
  • Parisella MG, Chianelli M, D'Alessandria C, Todino V, Mikolajczak R, Papini E, Dierckx RA, Scopinaro F, Signore A. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2012 Feb; 56(1): 90-8.
  • Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011; 52 (11): 1803-10.
  • D'Alessandria C, di Gialleonardo V, Chianelli M, Mather SJ, de Vries EF, Scopinaro F, Dierck RA, Signore A. Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol Imaging Biol. 2010; 12 (5): 539-46.
  • Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, Scopinaro F, Dierckx R, Signore A. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes. J Nucl Med. 2009 Oct; 50(10): 1683-91.
  • Bartolazzi A, D'Alessandria C, Parisella MG, Signore A, Del Prete F, Lavra L, Braesch-Andersen S, Massari R, Trotta C, Soluri A, Sciacchitano S, Scopinaro F. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS One. 2008; 3(11):e3768.
  • D'Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A, Scopinaro F, Caprilli R, Signore A. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies. Q J Nucl Med Mol Imaging. 2007 Dec; 51(4): 334-42.
  • Soluri A, Trotta C, Scopinaro F, Tofani A, D'Alessandria C, Pasta V, Stella S, Massari R. Radioisotope guided surgery with imaging probe, a hand-held high-resolution gamma camera. IEEE - Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers Detectors and Associated Equipment. 2007; 583 (2-3): 366-371.
  • Annovazzi A, D'Alessandria C, Bonanno E, Mather SJ, Cornelissen B, van de Wiele C, Dierckx RA, Mattei M, Palmieri G, Scopinaro F, Signore A. Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging. 2006 Apr; 33(4): 474-82.
  • Annovazzi A, Bonanno E, Arca M, D'Alessandria C, Marcoccia A, Spagnoli LG, Violi F, Scopinaro F, De Toma G, Signore A. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2006 Feb; 33(2): 117-26.
  • Signore A, Annovazzi A, Barone R, Bonanno E, D'Alessandria C, Chianelli M, Mather SJ, Bottoni U, Panetta C, Innocenzi D, Scopinaro F, Calvieri S. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med. 2004 Oct;45(10):1647-52.

 

Reviews

  • Bartolazzi A, Sciacchitano S, D'Alessandria C. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. Int J Mol Sci. 2018 Feb 2;19(2). pii: E445. doi: 10.3390/ijms19020445.
  • Signore A, Chianelli M, D'Alessandria C, Annovazzi A. Receptor targeting agents for imaging inflammation/infection: where are we now? Q J Nucl Med Mol Imaging. 2006 Sep;50(3):236-42.
  • Chianelli M, D'Alessandria C, Conti F, Priori R, Valesini G, Annovazzi A, Signore A. New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nucl Med Mol Imaging. 2006 Sep;50(3):217-25.
  • Annovazzi A, Bagni B, Burroni L, D'Alessandria C, Signore A. Nuclear medicine imaging of inflammatory/infective disorders of the abdomen. Nucl Med Commun. 2005 Jul;26(7):657-64.
  • Chianelli M, Parisella MG, D'Alessandria C, Corsetti F, Scopinaro F, Signore A. The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options. Q J Nucl Med. 2003 Dec;47(4):256-69.

 

Book Chapters

  • Signore A, Annovazzi A, Chianelli M, Capriotti G, D'Alessandria C, Biancone L, Bonanno E, Veneziani A, Scopinaro F. Inflammatory Bowel Diseases: the use of radiolabelled cytokines for in vivo evaluation of inflammatory activity. In: Nuclear medicine in the management of inflammatory and infectious diseases - when and how. A. Signore, M. Liberatore, F. Scopinaro, Eds. Springer-Verlag Pbl. Heidelberg 2002.

     
  • Signore A, Chianelli M, D'Alessandria C, Corsetti F, Annovazzi A, De Toma G, Scopinaro F. Diagnostic use of radiolabelled cytokines and chemokines. In: Technetium, Rhenium and other metals in Chemistry and Nuclear Medicine 6. Nicolini M, Mazzi U. Eds. SGE Editoriali Pbl., 2002; p. 637-645.

     
  • Signore A, Annovazzi A, Chianelli M, Capriotti G, D’Alessandria C, Biancone L, Bonanno E, Veneziani A, Scopinaro F. In: Nuclear medicine in the management of inflammatory and infectious diseases - When and How. Signore A, Liberatore M, Scopinaro F, Eds. Springer-Verlag Publ., (in press), 2002; p. 25-30

 

Additional abstracts and meeting presentations

http://apps.webofknowledge.com/Search.do?product=WOS&SID=F3WNOuzYYp8VuKI5zwV&search_mode=GeneralSearch&prID=d2b77002-e9a3-4e0b-8eed-a4eb347d080e

 

Additional scientific publications

http://www.ncbi.nlm.nih.gov/pubmed/?term=D%27Alessandria+C(link is external)

http://apps.webofknowledge.com/Search.do?product=WOS&SID=F3WNOuzYYp8VuKI5zwV&search_mode=GeneralSearch&prID=108e67d9-d295-4c50-911d-8600cd122b49